Evidence map›Paper›PMID 31728404›Full record

ArticleAdvanced biosystems2019

Biomimetic Nanoparticle Vaccines for Cancer Therapy.

Ashley V Kroll, Yao Jiang, Jiarong Zhou, Maya Holay, Ronnie H Fang, Liangfang Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced biosystems, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Tuning macrophages for atherosclerosis treatment.Regenerative biomaterials · 2023
    Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ashley V KrollDepartment of NanoEngineering and Moores Cancer Center, University of California San Diego, La Jolla, CA, 92093, USA.
Yao JiangDepartment of NanoEngineering and Moores Cancer Center, University of California San Diego, La Jolla, CA, 92093, USA.
Jiarong ZhouDepartment of NanoEngineering and Moores Cancer Center, University of California San Diego, La Jolla, CA, 92093, USA.
Maya HolayDepartment of NanoEngineering and Moores Cancer Center, University of California San Diego, La Jolla, CA, 92093, USA.
Ronnie H FangDepartment of NanoEngineering and Moores Cancer Center, University of California San Diego, La Jolla, CA, 92093, USA.
Liangfang ZhangDepartment of NanoEngineering and Moores Cancer Center, University of California San Diego, La Jolla, CA, 92093, USA.ORCID https://orcid.org/0000-0003-0637-0654

Funding

Cancer Researchers in Nanotechnology (CRIN)T32CA153915 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI KUMMEL, ANDREW CLYDE, ZHANG, DONG-ER · 2017 to 2021
$994k
NCI NIH HHS T32 CA153915
6 · The paper itself

Abstract

It is currently understood that, in order for a tumor to successfully grow, it must evolve means of evading immune surveillance. In the past several decades, researchers have leveraged increases in our knowledge of tumor immunology to develop therapies capable of augmenting endogenous immunity and eliciting strong antitumor responses. In particular, the goal of anticancer vaccination is to train the immune system to properly utilize its own resources in the fight against cancer. Although attractive in principle, there are currently only limited examples of anticancer vaccines that have been successfully translated to the clinic. Recently, there has been a significant push towards the use of nanotechnology for designing vaccine candidates that exhibit enhanced potency and specificity. In this progress report, we discuss recent developments in the field of anticancer nanovaccines. By taking advantage of the flexibility offered by nanomedicine to purposefully program immune responses, this new generation of vaccines has the potential to address many of the hurdles facing traditional platforms. A specific emphasis is placed on the emergence of cell membrane-coated nanoparticles, a novel biomimetic platform that can be used to generate personalized nanovaccines that elicit strong, multi-antigenic antitumor responses.

Indexed as

anticancer vaccinationantigen presentationbiomimetic nanoparticleimmunotherapynanomedicine

Identifiers

PMID31728404
PMCPMC6855307

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.